A Phase I Open-Label, Multi-Center Trial With Randomization to Dose to Evaluate the Safety and Tolerability of Topical Ocular PAN-90806 in Patients With Neovascular Age-Related Macular Degeneration (AMD)

Trial Profile

A Phase I Open-Label, Multi-Center Trial With Randomization to Dose to Evaluate the Safety and Tolerability of Topical Ocular PAN-90806 in Patients With Neovascular Age-Related Macular Degeneration (AMD)

Completed
Phase of Trial: Phase I/II

Latest Information Update: 14 Oct 2016

At a glance

  • Drugs PAN 90806 (Primary)
  • Indications Choroidal neovascularisation; Wet age-related macular degeneration
  • Focus Adverse reactions
  • Sponsors PanOptica
  • Most Recent Events

    • 14 Oct 2016 Results published in a PanOptoca media release.
    • 14 Oct 2016 Results presented during the 2016 Retina Subspecialty Day at the American Academy of Ophthalmology (AAO) Annual Meeting 2016, according to a PanOptica media release.
    • 27 Sep 2016 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top